Applied Dna Sciences INC 10-Q quarterly reports
Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.
BNB Plus Corp. reports a significant net loss in Q1 2026, driven by its strategic pivot to a digital asset treasury strategy and associated fair value losses on digital assets.
Applied DNA Sciences reports continued net losses and a going concern warning as it strategically exits non-core businesses to focus on nucleic-acid production for biopharmaceuticals.
Applied DNA Sciences is shifting its focus to Therapeutic DNA Production Services after exiting its DNA Tagging and Security Products and Services business, reporting a net loss of $6.0 million for the six months ended March 31, 2025.
10-Q: Applied DNA Sciences Reports Q1 2025 Results, Revenue Up but Losses Persist Amid Strategic Shift
Applied DNA Sciences saw revenue growth in Q1 2025 but continues to experience net losses as it focuses on Therapeutic DNA Production Services and exits its DNA Tagging and Security Products and Services business.
Applied DNA Sciences reported its Q3 2024 financial results, highlighting a net loss and raising concerns about its ability to continue as a going concern.
Applied DNA Sciences reported a net loss for the second quarter of 2024 and faces substantial doubt about its ability to continue as a going concern.
Applied DNA Sciences reported a net loss for the first quarter of fiscal year 2024, while focusing on the development of its Therapeutic DNA Production Services and MDx Testing Services.